I see the reduction as very decent considering the avg patient weighed around 225 lbs. I'll wait for the details to come out but I know the 24 week trial did not allow for dose adjustment. Every other trial allows this.
I think Alt made a big mistake not allowing adjustments as needed but if they're main goal was in dose finding I can see their point.
Altimmune (ALT) CEO Vipin Garg noted that the 15.6% mean weight loss with the 2.4 mg dose was associated with a mean weight loss of 32.2 lbs at 48 weeks and 48% of those on the 2.4 mg dose with baseline obesity no longer had obesity by the end of the study.
Market Data 
Markets 
AI
